A Phase 2 interventional study of Sildenafil in Persistent Pulmonary Hypertension of the Newborn, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Withdrawn. Open to participants aged Up to 72 Hours. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine the efficacy of iv sildenafil in term and near term infants with PPHN (persistent pulmonary hypertension of the newborn), by measuring the need for inhaled nitric oxide (iNO) or extracorporeal membrane oxygenation (ECMO) compared to a historical control group not treated with sildenafil.
40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.
Browse Persistent Fetal Circulation Syndrome studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
iv sildenafil
Drug: Sildenafil
Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
Efficacy - incidence of treatment failure
Time frame: Day 1-14
Need for inhaled nitric oxide or Extracorporeal membrane oxygenation
Time frame: Day 1-14
Changes in oxygenation index
Time frame: 6 & 12 hours
Changes in differential saturation
Time frame: 6 & 12 hours
Duration of mechanical ventilation
Time frame: Days 1-14
Time from initiation of sildenafil to inhaled nitric oxide or extracorporeal membrane oxygenation
Time frame: Days 1-14
No study locations are listed for this record.
The record gives a start of Mar 2012, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Persistent Fetal Circulation Syndrome →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →